These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28045357)

  • 1. Anticoagulation and Renal Insufficiency.
    Koulouri A; Calanca L; Mazzolai L
    Ther Umsch; 2016; 73(10):567-572. PubMed ID: 28045357
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Simeon L; Wuillemin WA
    Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
    [No Abstract]   [Full Text] [Related]  

  • 3. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
    Robert-Ebadi H; Righini M
    Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
    [No Abstract]   [Full Text] [Related]  

  • 4. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    Oberhofer E
    MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
    [No Abstract]   [Full Text] [Related]  

  • 5. [Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?].
    Buerke M; Hoffmeister HM
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):105-110. PubMed ID: 28074293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Edoxaban is safer than vitamin K antagonists].
    Einecke D
    MMW Fortschr Med; 2013 Sep; 155(16):20. PubMed ID: 24279137
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
    Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of anticoagulation control in atrial fibrillation.
    Lane DA; Lip GY
    Lancet; 2010 Sep; 376(9745):935-7. PubMed ID: 20801499
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
    Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
    Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Another novel oral anticoagulant matches warfarin.
    Mitka M
    JAMA; 2014 Jan; 311(3):233-4. PubMed ID: 24430308
    [No Abstract]   [Full Text] [Related]  

  • 14. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
    Pan EY; Sobieraj DM
    Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
    [No Abstract]   [Full Text] [Related]  

  • 15. Dabigatran versus warfarin for patients with non-valvular atrial fibrillation: is the patient the winner?
    Grave S
    Aust Nurs J; 2011 Dec-2012 Jan; 19(6):30-3. PubMed ID: 22329103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M; Lip GY
    Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stroke prevention in atrial fibrillation: another step sideways.
    Go AS; Singer DE
    Lancet; 2008 Jan; 371(9609):278-80. PubMed ID: 18294981
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
    Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
    Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of bleeding complications due to oral anticoagulant drugs].
    Riess H
    Laryngorhinootologie; 2015 Oct; 94(10):697-709. PubMed ID: 26468622
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
    Sardar P; Chatterjee S; Herzog E; Nairooz R; Mukherjee D; Halperin JL
    Can J Cardiol; 2014 Aug; 30(8):888-97. PubMed ID: 25064581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.